Avacta Group Plc (AVCT.L), a life sciences company, on Tuesday announced that it has appointed David Liebowitz as Chief Medical Officer.
Liebowitz will oversee the company's clinical strategy and progress as it moves forward with its targeted cancer therapies.
Liebowitz has more than three decades of experience and has most recently served as Senior Vice President of early-stage clinical development at Inovio Pharmaceuticals.
The company has also appointed Yulii Bogatyrenko as an advisor in business development. Bogatyrenko will help strengthen the company's business development efforts.
On Monday, Avacta closed trading at 31 pence on the London Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.